Breaking: Weight-Loss Drugs Spooked Medical Device Stocks. Did Investors Overreact?
When looking for the best stocks to buy and watch, focus on those with rising relative price strength.
One stock that fits that bill is Chemed (CHE), which saw a positive improvement to its Relative Strength (RS) Rating on Friday, rising from 63 to 90.
X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. This unique rating tracks market leadership by showing how a stock’s price action over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research shows that the best-performing stocks often have an 80 or better RS Rating as they launch their biggest climbs.
Looking For Winning Stocks? Try This Simple Routine
Chemed is building a cup without handle with a 574.66 buy point. See if the stock can clear the breakout price in heavy volume.
Earnings grew 25% last quarter, up from -3% in the prior report. Revenue also increased, from 4% to 7%.
The company earns the No. 2 rank among its peers in the Diversified Operations industry group. General Electric (GE) is the top-ranked stock within the group.
Get these newsletters delivered to your inbox & more info about our products & services. Privacy Policy & Terms of Use
YOU MAY ALSO LIKE:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD’s Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
See How To Reduce Risk, Increase Profits With Swing Trading
3/13/2023 A Relative Strength Rating upgrade for Chemed shows improving technical performance.
3/13/2023 A Relative Strength Rating upgrade for Chemed shows improving technical…
In the world of ESG investing, not all sustainability stocks are alike. (© Gary Neill)
Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20!
Get market updates, educational videos, webinars, and stock analysis.
Learn how you can make more money with IBD’s investing tools, top-performing stock lists, and educational content.
Notice: Information contained herein is not and should not be construed as an offer, solicitation, or recommendation to buy or sell securities. The information has been obtained from sources we believe to be reliable; however no guarantee is made or implied with respect to its accuracy, timeliness, or completeness. Authors may own the stocks they discuss. The information and content are subject to change without notice.
*Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade prices are not sourced from all markets.
Ownership data provided by Refinitiv and Estimates data provided by FactSet.
© 2000-2023 Investor’s Business Daily, LLC. All rights reserved